[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-31118":3,"doc-seo-31118":21},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":19,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"update_tm":20},31118,7971461740909,"Levi","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",8,"Research & Report","Neoadjuvant Nivolumab Plus Ipilimumab Versus Adjuvant Nivolumab in Macroscopic, Resectable Stage III Melanoma: The Phase 3 NADINA Trial","The phase 3 NADINA trial evaluates neoadjuvant immunotherapy with ipilimumab plus nivolumab, followed by response-driven adjuvant therapy, versus standard lymph node dissection followed by adjuvant nivolumab in macroscopic, resectable stage III melanoma. Patients naive to ICI and BRAFi/MEKi were randomized to receive two cycles of neoadjuvant therapy plus surgery, or standard treatment with adjuvant nivolumab. The primary endpoint, event-free survival from randomization, was assessed using Cox regression with an interim Haybittle-Peto rule. Neoadjuvant treatment significantly improved 12-month EFS (83.7% vs 57.2%; HR 0.32) with manageable toxicity profiles.","cbCaicF4aBUzkDzC","https://ap.wps.com/l/cbCaicF4aBUzkDzC","pdf",52949,1,1778619758,{"code":4,"msg":22,"data":23},"ok",{"site_id":24,"language":25,"slug":26,"title":13,"keywords":27,"description":14,"schema_data":28,"social_meta":63,"head_meta":65,"extra_data":67,"updated_unix":20},105,"en","neoadjuvant-nivolumab-plus-ipilimumab-versus-adjuvant-nivolumab-in-macroscopic-resectable-stage-iii-melanoma-the-phase-3-nadina-trial","",{"@graph":29,"@context":62},[30,47],{"@type":31,"itemListElement":32},"BreadcrumbList",[33,37,41,44],{"item":34,"name":35,"@type":36,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":38,"name":39,"@type":36,"position":40},"https://docshare.wps.com/document/","Document",2,{"item":42,"name":12,"@type":36,"position":43},"https://docshare.wps.com/document/research-report/",3,{"item":45,"name":13,"@type":36,"position":46},"https://docshare.wps.com/document/neoadjuvant-nivolumab-plus-ipilimumab-versus-adjuvant-nivolumab-in-macroscopic-resectable-stage-iii-melanoma-the-phase-3-nadina-trial/31118",4,{"url":45,"name":13,"@type":48,"author":49,"headline":13,"publisher":51,"fileFormat":54,"description":14,"dateModified":55,"datePublished":56,"encodingFormat":54,"isAccessibleForFree":57,"interactionStatistic":58},"DigitalDocument",{"name":9,"@type":50},"Person",{"url":34,"name":52,"@type":53},"DocShare","Organization","application/pdf","2026-05-14","2026-05-12",true,{"@type":59,"interactionType":60,"userInteractionCount":19},"InteractionCounter",{"@type":61},"ViewAction","https://schema.org",{"og:url":45,"og:type":64,"og:title":13,"og:site_name":52,"og:description":14},"article",{"robots":66,"canonical":45},"index,follow",{"doc_id":7,"site_id":24}]